Morphosys AG, founded in 1992 and based in Planegg near Munich, is an international biopharmaceutical company specializing in the development of innovative cancer therapies. The company has various antibody, protein and peptide technologies that it uses to research and develop both its own and partnered drug candidates.
Morphosys' most important technology is an antibody library called HuCAL®, which is used by scientists to generate human antibodies. This collection comprises more than ten billion different human antibodies in the form of a phage display bank. Morphosys makes the HuCAL® library available to several partner companies for license fees, either for the development of therapeutic agents based on monoclonal antibodies or for research purposes. Tremfya® (guselkumab), a drug based on HuCAL® technology, is currently on the market. Tremfya was generated using MorphoSys's proprietary antibody technology HuCAL® and received marketing authorization for the treatment of psoriasis in 2017.
In the portfolio
from 1996 to 2024
Investment manager
Brigitte Linseis
